Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.

Mateus de Oliveira TaveiraSheida NabaviYuker WangPeter TonellatoFrancisco J EstevaLewis C CantleyGerburg M Wulf

Published in: Journal of cancer research and clinical oncology (2017)

Mutational burden in heavily treated trastuzumab-resistant Her2-positive metastatic breast cancer is highly variable and not directly correlated with outcome. Activation of the MAPK/ERK pathway through mutations in EGFR, BRAF or KIT may mediate resistance to trastuzumab.

Keyphrases

metastatic breast cancer
signaling pathway
small cell lung cancer
pi k akt
epidermal growth factor receptor
tyrosine kinase
cell proliferation
copy number
dna methylation
metastatic colorectal cancer